Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Human Papillomavirus DNA Tests 4Colposcopy 4Watchful Waiting 3Biopsy 3Acetic Acid 3Transurethral Resection of Prostate 2Restraint, Physical 2Conization 2Blood Specimen Collection 2pembrolizumab 1human papillomavirus vaccine, L1 type 16, 18 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1artesunic acid 1artemisinin 1aldesleukin 1Vaccines 1Ultrasonography, Doppler 1Transdermal Patch 1Respiratory Function Tests 1Prochlorperazine 1Pregnancy Tests 1Positron-Emission Tomography 1Papanicolaou Test 1Ondansetron 1O(6)-codeine methyl ether 1Nicotine Replacement Therapy 1Mutagenesis, Insertional 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Dysplasia × Doxylamine × 1 year × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡